# HYBRIDOMA AND MYELOMA ANTIBODY COMBINING SITES

> **NIH NIH R01** · COLUMBIA UNIV NEW YORK MORNINGSIDE · 1988 · $286,599

## Abstract

The objective of these studies is to analyze the fine structure of the
antibody combining sites which bind a defined, site filling antigenic
determinant of six or seven Alpha(1 Yield 6)-linked glucose residues.
Changes in the amino acid sequence of the variable regions of heavy and
light chains of mouse hybridoma and myeloma anti-Alpha(1 Yield 6) dextrans
will be correlated with changes in combining site size, affinity and
idiotypic determinants.  The relative contributions of CDR1, 2, and 3 and
of VH and VL to the combining site will be assessed.  The origins of
antibody diversity (e.g., somatic or germ-line) to this well defined, T
independent antigen will be determined.  Chain recombination and in vitro
mutagenesis with expression of the mutagenized chains by gene transfection
will be used to further define the contribution of specific amino acid
residues to the combining specificity.

## Key facts

- **NIH application ID:** 3128471
- **Project number:** 5R01AI019042-06
- **Recipient organization:** COLUMBIA UNIV NEW YORK MORNINGSIDE
- **SAM.gov UEI:** F4N1QNPB95M4
- **Principal Investigator:** ELVIN A KABAT
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1988
- **Award amount:** $286,599
- **Award type:** 5
- **Project period:** 1983-09-30 → 1989-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3128471

## Citation

> US National Institutes of Health, RePORTER application 3128471, HYBRIDOMA AND MYELOMA ANTIBODY COMBINING SITES (5R01AI019042-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3128471. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*